Pulmatrix Closes $1M Private Placement of Preferred Stock at Premium Conversion Price, Advancing Merger
Summary
Pulmatrix announced the closing of a $1 million private placement of Series B Convertible Preferred Stock, convertible at a premium to the current stock price, as part of its planned merger with Eos SENOLYTIX.
Key Events
-
Private Placement Closed
Pulmatrix, Inc. closed a previously announced private placement of Series B Convertible Preferred Stock on April 16, 2026.
-
Capital Raised
The company received approximately $1 million in gross proceeds, intended for working capital and general corporate purposes.
-
Premium Conversion Price
The Series B Preferred Stock is convertible into common stock at a price of $2.20 per share, which is a premium to the current market price.
-
Part of Planned Merger
This transaction is an integral part of Pulmatrix's ongoing planned merger with Eos SENOLYTIX, Inc.
Analysis
Pulmatrix, a micro-cap company, has successfully closed a private placement raising $1 million, which is a substantial capital infusion relative to its market capitalization. A key positive detail is that the Series B Preferred Stock is convertible at $2.20 per share, a significant premium to the current stock price of $1.4387. This indicates investor confidence in a higher future valuation for the company. The financing is explicitly linked to the ongoing planned merger with Eos SENOLYTIX, Inc., suggesting progress on this strategic corporate event and providing necessary working capital.
At the time of this filing, PULM was trading at $1.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.9M. The 52-week trading range was $1.16 to $9.37. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.